{"id":"NCT03774407","sponsor":"Texas Tech University Health Sciences Center","briefTitle":"Vaginal Estriol in Multiple Sclerosis","officialTitle":"Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2019-06-20","primaryCompletion":"2020-11-10","completion":"2020-11-29","firstPosted":"2018-12-13","resultsPosted":"2022-09-21","lastUpdate":"2022-09-21"},"enrollment":21,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis","Neurogenic Bladder"],"interventions":[{"type":"DRUG","name":"vaginal estriol","otherNames":["estriol cream"]}],"arms":[{"label":"urogenital symptoms","type":"OTHER"},{"label":"remyelination","type":"EXPERIMENTAL"}],"summary":"Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.","primaryOutcome":{"measure":"Change in Bladder Control Scale (BLCS)","timeFrame":"baseline and 9 months","effectByArm":[{"arm":"Urogenital Symptoms","deltaMin":-9,"sd":null}],"pValues":[{"comp":"OG000","p":"0.002"}]},"eligibility":{"minAge":"40 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["24453710","23076892","26696956","24769473","11386586","25415166","19442988"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":[]}}